Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bexarotene + betamethasone dipropionate
- Development stage
- Phase 2
- Lead developer
- Almirall
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
LAS41004-IMP1 is an investigational topical ointment formulation developed by Almirall, S.A. for the treatment of mild to moderate plaque psoriasis. It is a fixed-dose combination product containing bexarotene, a synthetic retinoid that selectively activates retinoid X receptors (RXR), and betamethasone dipropionate, a potent corticosteroid that acts as a glucocorticoid receptor agonist. The combination aims to leverage the anti-proliferative and immunomodulatory effects of bexarotene alongside the anti-inflammatory and immunosuppressive properties of betamethasone dipropionate. Clinical development has focused on evaluating its efficacy in reducing psoriatic plaques while monitoring for potential side effects such as skin atrophy. The 'IMP1' designation refers to 'Investigational Medicinal Product 1,' distinguishing it as a specific formulation within clinical trial protocols.
- Other names
- bexarotene + betamethasone dipropionate
02
Targets
GR (Glucocorticoid receptor)RARA (Retinoic acid receptor alpha)RXRA (Retinoid X receptor alpha)RXRB (Retinoid X receptor beta)RXRG (RXRγ)
Beyond the preview
Go deeper on bexarotene + betamethasone dipropionate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bexarotene + betamethasone dipropionate.